Morningstar

Ocugen Inc OCGN

Stock XNAS Rating as of Oct 23, 2026

News

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

GlobeNewswire Oct 22, 2026, 11:00:00 AM
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

GlobeNewswire Oct 14, 2026, 10:30:00 AM
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PR Newswire Oct 8, 2026, 6:49:00 PM
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

GlobeNewswire Oct 6, 2026, 11:02:00 AM
Ocugen to Participate in Upcoming Scientific Conferences

GlobeNewswire Sep 30, 2026, 11:02:00 AM
Ocugen to Participate in Upcoming October Investor and Industry Conferences

GlobeNewswire Sep 29, 2026, 11:02:00 AM
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

GlobeNewswire Sep 25, 2026, 11:02:00 AM
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire Sep 1, 2026, 11:02:00 AM
Ocugen to Participate in Upcoming September Investor and Industry Conferences

GlobeNewswire Aug 25, 2026, 11:02:00 AM
Ocugen Provides Business Update with Second Quarter 2026 Financial Results

GlobeNewswire Aug 6, 2026, 11:02:00 AM
Ocugen to Participate in Upcoming August Investor Conferences

GlobeNewswire Jul 31, 2026, 11:02:00 AM
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire Jul 29, 2026, 11:01:00 AM
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

GlobeNewswire Jul 28, 2026, 8:01:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.